Schizophrenia : From Molecule to Public Policy. Conference. Santa Fe, NM, USA, 1998/10.
Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations.
Although psychosis is present in the majority of patients with schizophrenia, the prevalence, responsiveness to atypical antipsychotic drug therapy, and prediction of outcome of individual psychotic symptoms in a population of well-diagnosed patients with schizophrenia have not been conclusively established.
This paper examined the prevalence, responsiveness to the atypical antipsychotic olanzapine, and relationship to outcome of individual psychotic symptoms using data from a previously reported large multicenter, double-blind clinical trial of olanzapine (mean daily dose at endpoint=13.6 ± 6.9 mg/day).
The most frequently reported psychotic symptoms at baseline were delusions (65%), conceptual disorganization (50%), and hallucinations (52%), and the majority of patients (68%) experienced from one to three symptoms.
Additionally, with olanzapine treatment there were significant improvements (p<. 001) in baseline to endpoint Positive and Negative Symptom Scale (PANSS) psychotic item scores, with the largest effect sizes observed for hallucinatory behavior, unusual thought content, suspiciousness/persecution, and delusions. (...)
Mots-clés Pascal : Schizophrénie, Symptomatologie, Trouble cognition, Hallucination, Délire, Chimiothérapie, Olanzapine, Neuroleptique, Atypique, Psychotrope, Prévalence, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Traitement, Homme, Psychose, Thiéno benzodiazépine dérivé
Mots-clés Pascal anglais : Schizophrenia, Symptomatology, Cognitive disorder, Hallucination, Delusion, Chemotherapy, Olanzapine, Neuroleptic, Atypical, Psychotropic, Prevalence, Epidemiology, United States, North America, America, Treatment, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0396430
Code Inist : 002B02B03. Création : 22/03/2000.